We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

Intellia Therapeutics, Inc. shares declined over 5% on Monday morning after Morgan Stanley downgraded the stock to ‘Equal ...

NEW YORK, NY / ACCESS Newswire / February 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...

NEW YORK CITY, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...

Morgan Stanley lowered shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) from an overweight rating to an equal ...

Intellia Therapeutics, Inc. and Editas Medicine, Inc. are undergoing organizational restructuring and pipeline prioritization, aiming to optimize resources and extend the cash runway until 2027 ...

CEO John Leonard said the company will focus its resources largely on two late-stage programs amid a “challenging market environment.” Intellia Therapeutics Inc. is shedding employees and ...

Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep the engine running until a potential commercial launch in 2027.

Intellia Therapeutics, Inc. CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The inducement grant consisted of time-based restricted stock units ("RSUs”) for 21,863 shares of Intellia's common stock, ...